CMV infection is an important cause of morbidity and mortality in HCT recipients despite the introduction of posttransplant viral monitoring and preemptive antiviral therapy. We evaluated the use of HLA Class I tetramers in monitoring CMV-specific T-cell recovery to predict patients at risk for CMV-related complications. This prospective multicenter clinical trial obtained nearly 1,400 tetramer/allele results in >800 biweekly blood samples from 83 patients monitored for up to 1 year following transplantation. Major HLA types were included (A*0101,A*0201,B*0702,B*0801,B*3501). iTAg™ MHC Tetramers (Beckman Coulter) were used to enumerate CMV-specific CD8+ T-cells by flow cytometry using a singleplatform absolute counting method. Assay variability was ≤ 8%, and results were available within 3 hours. Delayed recovery of CMV-specific T-cells (<7 cells/µL in all blood samples during the first 65 days post-transplant) was found to be a significant risk factor for CMV-related complications; these patients were more likely to develop recurrent or persistent CMV infection (relative risk 2.6, CI 1.2-5.8, p=0.01) than patients showing rapid recovery, which was associated with protection from CMV-related complications (p=0.004). CMV tetramer-based immune monitoring, in conjunction with virologic monitoring, can be an important new tool that permits clinicians to assess risk of CMV-related complications and to guide preemptive therapeutic choices.
Introduction
Human cytomegalovirus (CMV) infects 60-90% of individuals worldwide and remains latent in the infected host. CMV-specific CD8+ cytotoxic T lymphocytes play a critical role in suppressing CMV reactivation. In healthy immunocompetent individuals, CMV infection is asymptomatic when an equilibrium is achieved and CMV-specific T cells control the persisting virus. In immunosuppressed hematopoietic stem cell transplant (HCT) recipients, CMV infection is an important cause of morbidity and mortality despite the introduction of routine post-transplant viral monitoring and the use of preemptive antiviral therapy 1 .
Direct measurement of frequencies of antigen-specific CD8+ T cells is now possible using major histocompatibility complex (MHC) tetramers. MHC tetramers are complexes between HLA class I or class II molecules and specific antigenic peptides conjugated to fluorochromes 2 . The antigen-specific T lymphocytes may be enumerated by flow cytometry without the requirement of in vitro stimulation, allowing for rapid and sensitive quantitative measurement of an individual patient's T cell response to a specific virus. Since development of a virus-specific response is crucial in suppressing CMV reactivation and preventing symptomatic CMV infection, and MHC tetramers allow measurement of this response, this study was undertaken to determine if tetramers may be useful in assessing the CMV risk in HCT recipients. Immune surveillance may provide additional information regarding the patient's risk of CMV reactivation, prolonged reactivation, recurrence of infection, or progression to CMV disease.
The objective of this prospective multicenter study was to evaluate the use of iTAg™ MHC Tetramers (Beckman Coulter) in enumerating CMV-specific CD8+ T cell reconstitution in allogeneic HCT recipients to predict patients at risk for recurrent or persistent CMV infection, CMV disease, or transplant related mortality (TRM).
Patients, materials and methods

Patients and study design
This multicenter prospective longitudinal clinical trial evaluated the use of tetramers in monitoring CMV-specific CD8+ T cell recovery following allogeneic HCT in 83 CMV-seropositive recipients. Patients were tested every 2 weeks from day 28 to day 100, every 2 to 4 weeks from day 101 to day 270, and were monitored for 1 year for viral results, lymphocyte counts, antiviral and immunosuppressive drug regimen, and clinical status. The protocol and informed consent form were reviewed and approved by each site's Institutional Review Board or Independent Ethics Committee, and informed consent was obtained from each subject in accordance with the Declaration of Helsinki.
CMV surveillance and preemptive therapy
All patients underwent weekly surveillance by pp65 antigenemia, DNAemia, or shell vial culture, with preemptive antiviral therapy as per institutional guidelines. All sites initiated preemptive therapy when CMV reactivation was detected and continued it until clearance of viremia. Ganciclovir was used for preemptive therapy unless the patients had concomitant neutropenia, which prompted the use of foscarnet.
Definitions
CMV infection was defined as assay positivity for each of the methods as follows: quantitative CMV DNA PCR: viremia reaching the threshold used at each institution for implementation of antiviral therapy. pp65 antigenemia: ≥ 2 positive cells per 200,000 cells (polymorphonuclear leukocytes, PMNs). Shell vial culture assay or tissue culture were positive if replicating virus was detected or isolated. Recurrent CMV infection was defined as two or more episodes (separated by negative CMV results). Persistent CMV infection was defined as positive results for 4 or more weeks. CMV disease was defined as biopsy proven organ-involvement (tissue-invasive), or CMV in bronchoalveolar lavage fluid.
Enumeration of CMV-specific CD8+ T cells
iTAg™ MHC Tetramers (Beckman Coulter) were used to enumerate CMV-specific CD8+ T cells in EDTA whole blood by flow cytometry using a single-platform absolute counting method. A panel of 5 CMV-derived peptides and corresponding major histocompatibility class 1 tetramers was used: pp50: A*0101 VTEHDTLLY; pp65: A*0201 NLVPMVATV, B*0702 TPRVTGGGAM, B*3501 IPSINVHHY; IE-1: B*0801 ELRRKMMYM. Donor and recipient were required to have one or more of the HLA types (A*0101, A*0201, B*0702, B*0801, B*3501) corresponding to available tetramers. These five HLA types are among the most common in many ethnic groups, For personal use only. on October 22, 2017. by guest www.bloodjournal.org From with coverage of 65% to 77% in Caucasian populations, 39% to 48% in Black populations, and 41% to 42% in Asian populations. [3] [4] [5] iTAg MHC Tetramers are complexes of four MHC (Major Histocompatibility Complex) molecules, which are associated with a specific peptide and bound to a fluorochrome. These complexes bind to a distinct set of T cell receptors (TCRs) on a subset of CD8+ T cells. By mixing tetramers with whole blood and using flow cytometry as a detection system, a count of all T cells that are specific for one peptide and its matched allele is provided, regardless of functionality. Tetramers allow direct measurement of disease-specific T cell responses. The iTAg Tetramers, which have been constructed from mutated HLA molecules to minimize CD8-mediated binding of HLA to cell surface CD8, show a greatly diminished binding to the general population of CD8 cells, but retain peptidespecific binding, 2 thus facilitating accurate discrimination of rare, specific T cells.
In this study, SA-PE-conjugated iTAg MHC Tetramers were used to enumerate CMV-specific CD8+ T cells by flow cytometry using a single-platform absolute counting method. This is a two-panel assay. Panel 1 determines absolute CD4+ and CD8+ T cell counts. Panel 2 determines the percentage of CD8+ T cells that are CMVspecific. Absolute counts of CMV-specific T cell subsets were calculated by multiplying the absolute CD8+ T cell count (determined in Panel 1) by the results from Panel 2. Tetramer values in this study were expressed in terms of percentage of the total CD8+ cells that were CMV-specific (CMV tetramer+ %), as well as CMV tetramer+ absolute counts (cells/μL).
For each specimen, a minimum of three tubes were required as follows (as previously described in detail 
Healthy normal control subjects
Observed tetramer ranges were established for healthy CMV sero-negative donors and healthy CMV seropositive donors. Testing was performed using all five CMV tetramers.
Endpoints and statistical analysis
The objective of the study was to evaluate the use of tetramers in enumerating CMV-specific CD8+ T cells to determine if tetramers can be used to assess CMV-specific immune status and risk of recurrent or persistent CMV infection, CMV disease, or transplant related mortality following allogeneic HCT. The analysis also determined if CMV-specific CD8+ T cell counts were an independent risk factor that can be used in conjunction with other known factors in identifying patients at risk of CMV infection and CMV-related complications.
The study endpoints were recurrent or persistent CMV infection as measured by each institution's standard method for virologic monitoring (quantitative CMV DNA PCR, pp65 antigenemia, shell vial culture), CMV disease or TRM. Endpoints were analyzed individually and as a composite.
To determine if CMV-specific CD8+ T cells were protective against CMV infection, the analysis evaluated recurrent or persistent CMV infection or CMV disease occurring after cellular repopulation, i.e. to evaluate if the presence or absence of these CMV-specific T cells would predict patients at risk for future episodes of recurrent or persistent infection or CMV disease. The maximum response of any individual allele / tetramer (A1, A2, B7, B8, B35) within an individual patient was used in the analysis. A total of 83 subjects met study entry criteria with 3 or more blood samples (or early death with CMV complications) and were included in the analysis.
A Chi-square analysis compared CMV tetramer recovery (rapid / delayed) vs. recurrent or persistent CMV infection or CMV disease (present / absent). Based on the Chi-square 2x2 tables, the Relative Risk (RR) (with 95% confidence intervals) of recurrent or persistent CMV Infection, CMV disease, or transplant-related mortality (TRM) was calculated. Univariate and bivariate logistic models assessed the predictive power of possible risk factors. Kaplan-Meier survival curves and cumulative incidence curves were used to assess time of event onset.
Results
Patient demographics
Data were analyzed for 83 allogeneic HCT recipients. Demographic and clinical characteristics are shown in Table 1 . Median follow-up was 9 months (range 2-12 months). Shorter follow-up times were primarily due to early deaths. The study protocol required blood draws and tetramer testing every 2 weeks from day 28 to day 100 (days 28, 42, 56, 70, 84, 98) post transplantation. Compliance rates with this schedule were ≥ 90% at all sites.
Tetramer recovery and risk of CMV infection and disease
To compare "CMV Tetramer Recovery" (rapid / delayed) and "Recurrent or Persistent CMV Infection or CMVD" (absent / present), a series of 2 x 2 Chi-square analyses were performed. Only those subjects with at least 5 months of viral test monitoring results (n = 72) were included in this analysis (median 9 months), allowing sufficient time to measure potential episodes of recurrent or persistent viral reactivation. Inclusion of patients with limited follow-up would introduce bias since the viral reactivation status was indeterminate due to insufficient data.
The first step in this analysis was to assess recovery kinetics, i.e. to define and evaluate "rapid" versus "delayed" recovery of CMV-specific immunity. A range of cutoff days post-transplant (60 to 100 days) was analyzed. Table  2a presents relative risk results for a tetramer threshold of 7 cells/μL; comparable tables were generated for tetramer thresholds between 2 and 10 cells/μL (data not shown). Similar patterns of results were observed for each tetramer threshold, with day 65 yielding the highest relative risk and the fewest "low risk" patients above the tetramer threshold with CMV complications. By Day 65, the majority of patients had at least 3 blood samples with tetramer results (86% compliance rate with the biweekly sampling schedule at days 28, 42, 56). Use of a cutoff day prior to day 65 yielded an insufficient number of blood draws and tetramer results per patient to be certain of the predictive validity. Use of a cutoff day after day 65 showed increasing difficulty in distinguishing between the "rapid" and "delayed" recovery groups as progressively more patients showed reconstitution of immunity approaching day 100, and was therefore less predictive. Use of day 65 as a cutoff clearly grouped patients into "rapid" and "delayed" recovery groups and was strongly associated with patient outcome.
The second step was to define "protective tetramer recovery", that is, to determine the tetramer threshold associated with protection from recurrent or persistent CMV infection or CMV disease. A range of CMV tetramer cell counts was evaluated (2 to 10 cells/μL). Table 2b presents relative risk results for day 65; comparable tables were generated for days 60 to 100 (data not shown). Similar patterns of results were observed for each cutoff day tested, with a threshold of 7 cells/μL yielding the highest relative risk (2.83), the greatest statistical significance (p = 0.004), and the fewest "low risk" patients with CMV complications (18%) (range: 18% to 28%). Table 3 shows that rapid recovery (≥ 7 cells/μL in any blood sample during the first 65 days post-transplant) was associated with protection from CMV-related complications (p = 0.004). In this group, 18% (6/34) developed recurrent or persistent CMV infection or CMV disease, whereas half (50%, 19/38) developed CMV complications in the delayed recovery group. Table 4a shows the relative risks with 95% confidence intervals for individual endpoints and composite endpoints. Results showed that delayed recovery of CMV-specific CD8+ T cells (< 7 cells/µL in all blood samples during the first 65 days post-transplant) predisposes patients to CMV-related complications. These patients are more likely to develop recurrent or persistent CMV infection, CMV disease, and fatal complications than patients showing rapid recovery.
Probability of recurrent or persistent CMV infection or CMVD
A total of 25 patients developed recurrent (n = 16) or persistent (n = 17) CMV infection or CMVD (n = 9). The cumulative incidence of recurrent or persistent CMV infection or CMVD is presented in Figure 1 . Patients with delayed recovery of CMV-specific CD8+ T cells were significantly more likely to develop CMV infection or disease than those patients with rapid recovery (p = 0.003).
Survival
Of the 83 patients in this study, 16 died of transplant-related complications. The Kaplan-Meier survival curve is shown in Figure 2 . Patients with delayed recovery of CMV-specific CD8+ T cells were less likely to survive (transplant-related mortality) than those patients with rapid recovery, although this was not statistically significant (p = 0.08) due to the relatively small number of deaths during the study period. Figure 3 shows examples of individual patient graphs with tetramer absolute cell counts and viral results over time (days post transplant). The first patient showed delayed recovery (< 7 cells/µL in all blood samples during the first 65 days); recurrent/persistent viremia was observed. The second patient (monitored with multiple tetramers) showed rapid recovery (at least 1 allele / tetramer ≥ 7 cells/µL in at least one blood sample before Day 65); no viremia was observed. Tetramer results are shown for A*0101, A*0201, and B*0801. Rapid recovery was observed for two of the three alleles.
Examples of immune reconstitution patterns
Individuals may respond with one or more alleles, and the responses may differ between alleles ( Figure 3 ). The maximum response of any allele / tetramer (A1, A2, B7, B8, B35) within an individual patient was used to determine whether or not the patient recovered CMV immunity. Of the 83 subjects, 44 were A1, A2, B7, B8, or B35 alone; 21 subjects had some combination of two of the relevant alleles; 16 subjects had three alleles; and 2 subjects had four alleles.
Correlation between tetramer absolute count and tetramer percent
Tetramer percent (%) and absolute cell counts (cells/µL) are moderately correlated (r = 0.66, n = 1,387 tetramer/allele results in 804 blood samples in 83 patients), but not strong enough to assume they provide the same information. Cell count is a more accurate reflection of CMV immune status than percent, and a more reliable predictor of patient outcome. It is possible to have the same tetramer percent in two different patients, but very different absolute cell counts depending upon the total CD8+ cell counts.
Allogeneic HCT recipients, observed tetramer ranges
The observed range of tetramer values for allogeneic stem cell transplant recipients in this study was 0 to 440 cells/μL (median = 3.33, mean ± SD = 25.45 ± 55.42, upper 95 th percentile = 149.12), or 0 to 42% (median = 1.53, mean ± SD = 4.29 ± 6.54, upper 95 th percentile = 18.80).
Of the 72 patients in the relative risk analysis, 47% (34/72) had at least one sample with a tetramer value greater than or equal to 7 cells/μL at any time during the first 65 days post-transplant.
Healthy control subjects, observed tetramer ranges
Whole blood from 72 healthy normal control subjects was tested, consisting of 36 donors each that were CMV sero-negative and CMV sero-positive. A total of 99 distinct tetramer/allele results were obtained, consisting of 57 sero-negative results and 42 sero-positive results using the appropriate allele matched tetramers for each donor.
The observed range based on CMV sero-positive donors was 0 to 47 cells/μL (median = 4.03, mean ± SD = 6.96 ± 9.49, upper 95 th percentile = 24.50), or 0 to 9% (median = 0.85, mean ± SD = 1.51 ± 1.79, upper 95 th percentile = 5.40). All of the CMV sero-negative donors tested had values below the limit of detection (1.0 cell/μL, 0.2%).
A greater proportion of transplant patients (47%, 34/72) had elevated tetramer values (≥ 7 cells/μL) compared to the healthy control subjects (29%, 12/42). The impaired immune system in transplant patients leads to frequent CMV reactivation and generation of CMV-specific T cells. In healthy controls, an equilibrium between T cells and virus has been achieved and high values in either viral load or T cell response are rarely observed. Tetramer values obtained in the healthy control subjects are not applicable to transplant patient management and are provided for reference only.
Comparison of tetramer and CD8+ and CD4+ absolute counts
. CMVspecific CD8+ (tetramer+) absolute counts (cells/μL) and total CD4+ absolute counts (cells/μL) showed a negligible correlation (r = 0.14, y = 0.03x + 12.71).
Univariate and bivariate logistic regression analysis
Possible risk factors were examined in a univariate analysis for their association with recurrent or persistent CMV infection or CMV disease. The 13 factors examined included conditioning regimens (myeloablative / nonmyeloablative), use of ATG, HLA mismatch, unrelated donor status, donor CMV serology (negative), source of stem cells, age, sex, acute graft-versus-host disease (aGVHD) (maximum grade ≥ 2), high-dose steroids, and delayed CD4+, CD8+, and tetramer counts (< 7 cells/μL).
Only five of the 13 variables (donor CMV serology, aGVHD, CD4+, CD8+, tetramer+ counts) showed a significant relationship (p < 0.05) with recurrent or persistent CMV infection or CMV disease in univariate analysis. The study sample size did not allow for simultaneous inclusion of all possible risk factors in a multivariate analysis. Therefore, individual bivariate logistic regression models were run to control for sample size. Tetramer recovery was paired with each of the other covariates in bivariate models. Results showed that delayed tetramer recovery by day 65 after HCT was independently associated with recurrent or persistent CMV infection or disease (Table  4b) as a significant risk factor and is not a surrogate for other known risk factors.
Examination of general T-cell reconstitution data showed that 39% of patients (28/72) had rapid recovery of total CD4+ cells (≥ 100 cells/μL within the first 65 days) but delayed recovery of CMV-specific CD8+ T cells; 44% (11/25) of patients with poor outcomes were in this group. In addition, 36% of patients (26/72) had rapid recovery of total CD8+ cells (≥ 100 cells/μL within the first 65 days) but delayed recovery of CMV-specific CD8+ T cells; 40% (10/25) of patients with poor outcomes were in this group.
Discussion
The measurement of T cell responses to pathogens, autoantigens, and tumor-derived antigens by MHC tetramers has become an established technique in preclinical research, and is becoming increasingly important for clinical trial monitoring of responses to vaccines and correlating natural T cell responses with clinical outcomes. The current study demonstrates the effectiveness of tetramer-based immune monitoring as a promising new tool in patient management.
This study is the largest prospective multicenter clinical trial to date evaluating the use of tetramers in allogeneic stem cell transplant recipients, with nearly 1,400 tetramer/allele results in over 800 biweekly blood samples from 83 patients monitored for up to 1 year following transplantation. The major HLA types were included (A*0101, A*0201, B*0702, B*0801, and B*3501). All sites followed the same standardized and optimized tetramer flow cytometry protocol using a single-platform absolute counting method that produced both frequency (%) and absolute cell count (cells/μL) results. A recent study demonstrated this iTAg MHC Tetramer-CMV assay to be simple, rapid, reproducible, and useful for assessing CMV-specific T cells across multiple centers at clinically relevant ranges. 6 Results from the current study demonstrate utility for this tetramer assay in monitoring CMV-specific CD8+ T cells to assess immune status and risk of recurrent or persistent CMV infection or CMV disease (CMVD) in immunosuppressed stem cell transplant recipients, allowing clinicians to further refine pre-emptive therapeutic strategies in appropriate high-risk populations.
Rapid recovery (≥ 7 cells/μL in any blood sample during the first 65 days post-transplant) of CMV-specific CD8+ T cells (tetramer+ cells) was associated with protection from recurrent or persistent CMV infection or CMVD. Delayed recovery (< 7 cells/μL in all blood samples during the first 65 days post-transplant) of CMV-specific CD8+ T cells predisposes patients to CMV-related complications. These patients are 2.6 times more likely to develop recurrent or persistent CMV infection, 6.4 times more likely to develop CMV disease, and 2.4 times more likely to develop fatal complications than patients showing rapid recovery.
Other possible risk factors were examined for their association with recurrent or persistent CMV infection or CMVD. Donor CMV serology, moderate to severe aGVHD, and delayed CD4+, CD8+, and CMV-specific CD8+ T cell counts were shown to have a significant relationship with CMV infection. CMV-specific CD8+ T cell counts were found to have independent predictive power as a significant risk factor and are not a surrogate for other known risk factors.
Examination of cellular reconstitution data showed that 44% of patients with poor outcomes had rapid recovery of total CD4+ cells but delayed recovery of CMV-specific CD8+ T cells. In addition, 40% of patients with poor outcomes had rapid recovery of total CD8+ cells but delayed recovery of CMV-specific CD8+ T cells. For these patients, monitoring of total CD4+ cells or total CD8+ cells post-transplant was not sufficient to detect patients at risk of CMV infection and disease. Tetramer-based monitoring alone allowed identification of these high-risk patients.
CMV-specific CD8+ (tetramer+) absolute counts showed a moderate correlation with total CD8+ absolute counts (r = 0.57) and a negligible correlation with total CD4+ absolute counts (r = 0.14). Tetramers provide unique information not available with these existing monitoring tests.
The observed range of tetramer values for allogeneic stem cell transplant recipients in this study was 0 to 440 cells/μL, or 0 to 42%. 47% of patients had at least one sample with a tetramer value greater than or equal to 7 cells/μL at any time during the first 65 days post-transplant.
Monitoring individual patients over time using multiple tetramers showed that individuals may respond with one or more alleles, and the responses may differ between alleles. The maximum response of any allele / tetramer (A1, A2, B7, B8, B35) within an individual patient was used to determine whether or not the patient recovered CMV immunity. It was observed that A1 and B7 tended to generate a stronger response than B8 and A2, but not in every case. Despite this diversity of response, a majority of patients (82%) capable of mounting a CMV-specific immune response (regardless of allele) appeared to be protected against recurrent or persistent infection or CMV disease. All five alleles / tetramers in this study showed a strong response in at least one patient, and correlated with protection against recurrent or persistent CMV infection or CMV disease in at least one patient. The results were consistent across alleles, i.e. rapid recovery of CMV immunity (≥ 7 cells/µL by any allele) appears to be associated with protection against CMV infection or disease.
Not all patients and alleles are covered with the tetramer panel used in our study. Research into other alleles and epitopes and the availability of additional tetramers in the future may improve results further. Rapid CMV-specific T cell recovery indicates an immune system capable of mounting a response. However, an absence of detectable CMV-specific T cells (delayed recovery) may be due to an impaired immune system or to the unavailability of all relevant tetramers for a specific patient. We cannot assess if another unmeasured allele is controlling the viremia. A "negative" tetramer finding may actually mean we are not measuring the more responsive allele. Despite this limitation, the panel of five tetramers in this study were highly effective in identifying high and low risk patients using only the available alleles / tetramers representing the most common HLA types.
Earlier studies in which tetramers were used to monitor the reconstitution of CMV-specific CD8+ T lymphocytes also showed a relationship between the number of cells and the occurrence of CMV reactivation and CMV disease. [7] [8] [9] [10] These studies primarily focused on enumeration of lymphocytes restricted by HLA-A2 and HLA-B7 molecules because these alleles are among the most common HLA subtypes in many ethnic groups, with a frequency of up to 40% and 13% respectively in Caucasian populations, 19% and 10% in Black populations, and 25% and 4% in Asian populations. [3] [4] [5] In the current study, the panel of five MHC tetramers expanded coverage up to 77% in Caucasian populations, 48% in Black populations, and 42% in Asian populations. [3] [4] [5] Previously, we used tetrameric complexes to quantify CMV-specific T cells in partially T-cell-depleted grafts of 18 CMV-seropositive HCT recipients, and monitored recovery of these T cells during the first 12 months after HCT. 7 We found that the number of CMV-specific cells in the grafts correlated inversely with the number of preemptive ganciclovir courses administered. Thirteen of 14 patients who did not develop CMV disease regenerated CMVspecific T cells. Four patients developed CMV disease despite preemptive ganciclovir treatment and all had failed to regenerate CMV-specific cells. These and current results showed that regeneration correlated with protection against progressive CMV infection and CMV disease, suggesting that enumeration of CMV-specific T cells in the grafts and monitoring of these cells after HCT may provide a new method to identify patients at risk of developing CMV disease.
Cwynarski et al 8 used HLA tetramers to prospectively monitor the recovery of CMV-specific T cells in 24 recipients of allogeneic stem cell transplants. They found that recovery of CMV-specific cells was rapid and reached up to 21% of all CD8+ T cells. Recovery of CMV-specific T cells to levels greater than 10 cells/µL was associated with protection from CMV disease. It was concluded that use of HLA tetramers is valuable for monitoring T cell responses and may assist in the development of adoptive CMV T cell immunotherapy.
In contrast, Morita-Hoshi and colleagues 11 reported that CMV disease could occur after HCT even in patients with > 10 cells/µL. Possible explanations for these discrepant findings may be important differences in how the CMVspecific CD8+ T lymphocytes were enumerated and CMV reactivation was monitored. Timing of tetramer testing is also critical; results of our current study indicate that a single sample at 30 days is not sufficient to assess risk of CMV reactivation.
Aubert et al
9 correlated CMV-specific T cells in 11 HCT recipients with viral replication and clinical status, and showed that the level of tetramer-positive T cells provides an assessment of CMV immune reconstitution. Most patients with seropositive donors reconstituted long-term immunity, unless prolonged immunosuppression to control GVHD was required. They concluded that the use of tetramers in conjunction with quantitative CMV DNA PCR testing provide potential measures that can in the future be a guide to clinical management.
Ozdemir et al 10 did not find a relationship between the ability to control CMV reactivation and the recovery of sufficient numbers of CMV-specific T cells. However, this study did not test for rate of CMV-specific T cell recovery soon after HCT; a single tetramer result was obtained from a blood sample drawn at three months following HCT. Our study findings indicate that tetramer testing every two weeks from day 28 to day 65 (3 to 4 test results) identifies patients with delayed recovery at risk of viral reactivation. A single tetramer result at three months cannot distinguish between the "delayed" (high risk) and "rapid" (low risk) recovery groups. In contrast, biweekly tetramer results in the second and third months were strongly associated with patient outcome.
Several studies have assessed intracellular cytokine production following CMV-specific T-cell stimulation, and found that the inability to control CMV reactivation may also be related to impaired function of antigen-specific CD4+ and CD8+ T cells. [10] [11] [12] [13] Future studies may show an additive ability to predict high risk patients by combining both functional analysis and cellular count rate of recovery.
Conclusions
CMV tetramer-based immune monitoring, in conjunction with virologic monitoring, can be an important new tool that permits clinicians to assess the risk of CMV-related complications and to guide preemptive therapeutic choices. CMV tetramer testing performed every other week starting on Day 28 post-transplant allows patients to be divided into two risk groups: "Rapid Recovery, Low Risk" and "Delayed Recovery, High Risk".
Rapid Recovery, Low Risk Patients: If any tetramer result for any allele in any blood sample between Day 28 and Day 65 is greater than or equal to the threshold of 7 cells/μL, then the patient has shown rapid recovery of CMVspecific immunity and is at low risk of developing recurrent or persistent CMV infection or CMV disease. For these low-risk patients, virologic monitoring should be continued following current practice. Studies are needed to determine how long virologic monitoring should be continued, and whether or not preemptive therapy may be reduced or introduced at a higher viral load threshold.
Delayed Recovery, High Risk Patients: If all tetramer results from all blood samples between Day 28 and Day 65 are below the threshold of 7 cells/μL, then the patient has shown delayed recovery of CMV-specific immunity and is at high risk of developing recurrent or persistent CMV infection or CMV disease. For these high-risk patients, we suggest that virologic monitoring and pre-emptive strategies should be continued beyond 100 days posttransplant; immunologic monitoring with tetramers may prove useful in determining when virologic surveillance can be discontinued. Table 4a . Relative risks for individual endpoints and composite endpoints. Delayed recovery of CMV-specific CD8+ T cells (< 7 cells/µL in all blood samples during the first 65 days post-transplant) is a significant risk factor for CMV-related complications. Examples of individual patient graphs with CMV-specific CD8+ T cell absolute counts (tetramer+ cells/µL) and viral results over time. The first patient showed delayed recovery (< 7 cells/µL in all blood samples during the first 65 days); recurrent/persistent CMV viremia was observed. The second patient (monitored with multiple tetramers) showed rapid recovery (at least 1 allele / tetramer ≥ 7 cells/µL in at least one blood sample before Day 65); no viremia was observed.
